Novavax Reports Costs Tied to Exit/Disposal Activities

TL;DR

**NVAX is reporting costs for exiting or disposing of activities, brace for potential one-time charges.**

AI Summary

Novavax, Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 30, 2024, related to "Cost Associated with Exit or Disposal Activities." This filing indicates that the company is undergoing some form of restructuring or winding down certain operations, which could involve significant costs. For investors, this matters because such activities often lead to one-time expenses that can impact short-term profitability and may signal a shift in the company's strategic focus or a response to underperforming assets.

Why It Matters

This filing signals potential restructuring or asset divestment, which could lead to one-time charges impacting Novavax's financial performance.

Risk Assessment

Risk Level: medium — The filing indicates potential costs and strategic shifts, which introduce uncertainty regarding future financial performance and operational focus.

Analyst Insight

A smart investor would monitor Novavax's upcoming financial reports for the specific dollar amounts of these exit or disposal costs and any further details on the nature of these activities, as they could impact future profitability and strategic direction.

Key Players & Entities

• NOVAVAX, INC. (company) — the registrant filing the 8-K
• January 30, 2024 (date) — date of the earliest event reported
• January 31, 2024 (date) — date the 8-K was filed
• Delaware (company) — state of incorporation for Novavax
• NVAX (company) — trading symbol for Novavax
• The Nasdaq Global Select Market (company) — exchange where Novavax's common stock is registered

Forward-Looking Statements

• Novavax will report specific financial charges related to exit or disposal activities in its next quarterly earnings report. (NOVAVAX, INC.) — high confidence, target: Q1 2024 Earnings Report
• The 'exit or disposal activities' may involve divesting non-core assets or streamlining certain operational segments. (NOVAVAX, INC.) — medium confidence, target: Mid-2024

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Select
• $4 million — ted to record a charge of approximately $4 million to $7 million related to one-time emplo
• $7 million — a charge of approximately $4 million to $7 million related to one-time employee severance

Filing Documents

• nvax-20240130.htm (8-K) — 35KB
• 0001000694-24-000003.txt ( ) — 158KB
• nvax-20240130.xsd (EX-101.SCH) — 2KB
• nvax-20240130_lab.xml (EX-101.LAB) — 23KB
• nvax-20240130_pre.xml (EX-101.PRE) — 12KB
• nvax-20240130_htm.xml (XML) — 3KB

05. Costs Associated with Exit or Disposal Activities

Item 2.05. Costs Associated with Exit or Disposal Activities. As previously announced, Novavax, Inc. (the "Company") has recently prioritized reducing its annual combined research and development and selling, general and administrative spend. In connection with those plans, on January 30, 2024, the Board of Directors of the Company approved an approximately 12% reduction of its global workforce, comprised of an approximately 9% reduction in the Company's full-time employees and the remainder comprised of contractors and consultants. The Company expects the full annual impact of the cost savings to be realized in 2025 and approximately 85% of the annual impact, excluding one-time charges, to be realized in 2024 due to timing of implementing the measures and the applicable laws, regulations and other factors in the jurisdictions in which it operates. The Company is expected to record a charge of approximately $4 million to $7 million related to one-time employee severance and benefit costs, the majority of which is expected to be incurred in the first quarter of 2024. Upon completion, the resulting Company workforce is expected to be approximately 30% lower as compared to the end of the first quarter of 2023. This Current Report on Form 8-K includes forward-looking statements including the Company's priorities, the size and timing of the Company's workforce reduction, the amount and timing of the charges and cash expenditures resulting from the workforce reduction, and the expected timing and impact of cost savings from the global restructuring and cost reduction plan. Generally, forward-looking statements can be identified through the use of words or phrases such as "believe," "may," "could," "will," "would," "possible," "can," "estimate," "continue," "ongoing," "consider," "anticipate," "intend," "seek," "plan," "project," "expect," "should," "would," "aim," or "assume," the negative of these terms, or other comparable terminology, although not all forward-looki

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVAVAX, INC. Date: January 31, 2024 By: /s/ Mark J. Casey Name: Mark J. Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR